Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Evelyn Fischer is active.

Publication


Featured researches published by Evelyn Fischer.


Eurointervention | 2010

PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study

Y Bayard; Heyder Omran; Petr Neuzil; Leif Thuesen; M Pichler; Edward Rowland; Angelo Ramondo; Witold Rużyłło; Werner Budts; Gilles Montalescot; Pedro Brugada; Patrick W. Serruys; Alec Vahanian; Jf Piechaud; Antonio L. Bartorelli; Jean Marco; Peter Probst; Karl-Heinz Kuck; Stefan Ostermayer; Franziska Büscheck; Evelyn Fischer; Michaela Leetz; Horst Sievert

The European PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study was performed to determine the safety and efficacy of left atrial appendage occlusion by catheter technique. Embolic stroke due to atrial fibrillation is a common observation, especially in the elderly. Most thrombi in atrial fibrillation form in the left atrial appendage (LAA), its occlusion may therefore reduce the incidence of stroke in these patients.


American Journal of Cardiology | 2008

Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex versus Helex occluder).

Margaret Taaffe; Evelyn Fischer; Andreas Baranowski; Nicolas Majunke; Corinna Heinisch; Michaela Leetz; Ralph Hein; Y Bayard; Franziska Büscheck; Madlen Reschke; Ilona Hoffmann; Nina Wunderlich; Neil Wilson; Horst Sievert

This randomized trial compared procedural complications and 30-day clinical outcomes of 3 patent foramen ovale (PFO) closure devices (Amplatzer, Helex, and CardioSEAL-STARflex). It examined 660 patients (361 men, 299 women, mean age 49.3+/-1.9 years), with 220 patients per group. All patients had a history of paradoxical embolism. All PFO closures were successful technically. Exchange of devices for others was most frequently required for the Helex occluder (7 of 220) and 2 of 220 in either of the other groups. Three device embolizations in the Helex group were retrieved and replaced successfully. One patient with a Helex occluder developed a transient ischemic attack and recovered without treatment. A hemopericardium in that group was punctured without affecting the device. One tamponade in the Amplatzer group required surgical device explantation. In 8 of 660 patients in the CardioSEAL-STARflex group, thrombi resolved after anticoagulation. Sixteen patients (11 in the CardioSEAL-STARflex group, 3 in the Amplatzer group, and 2 in the Helex group) had episodes of atrial fibrillation. PFOs were closed completely in 143 of 220 patients (65%) in the Amplatzer group, 116 of 220 patients (52.7%) in the Helex group, and 137 of 220 patients (62.3%) in the CardioSEAL-STARflex group at 30 days with significant differences between the Helex and Amplatzer occluders (p=0.0005) and the Helex and CardioSEAL-STARflex occluders (p=0.0003). PFO closure can be performed safely with each device. In conclusion, the Helex occluder embolized more frequently. Device thrombus formation and paroxysmal atrial fibrillation were more common with the CardioSEAL-STARflex occluder.


Circulation | 2007

Transcatheter Closure of Patent Foramen Ovale Without an Implant: Initial Clinical Experience

Horst Sievert; Evelyn Fischer; Corinna Heinisch; Nico Majunke; Albrecht Roemer; Nina Wunderlich

Background— Currently available catheter techniques for closure of a patent foramen ovale (PFO) rely on the placement of an implantable closure device. The objective of the Paradigm I study was to evaluate the safety and feasibility of transcatheter closure of PFO using radiofrequency energy without an implanted device in patients with cryptogenic stroke or transient ischemic attack. Methods and Results— Thirty patients were enrolled (15 females; mean age 48 years). Mean PFO size was 8.5±2.7 mm. Technical success (ie, successful application of radiofrequency energy) was achieved in 27 patients. The remaining 3 patients received an implantable closure device. All 30 patients were free from serious procedure-related adverse events. No recurrent strokes, deaths, or perforations occurred as a result of the procedure. The mean follow-up was 6 months, and 13 (43%) of the 30 patients experienced PFO closure after the first procedure. Nine of the patients whose PFOs remained patent after the first procedure elected to receive a second procedure using radiofrequency. The PFO was closed for 6 of those patients after the second procedure, which resulted in a secondary closure rate of 63%. Conclusions— This study demonstrates that transcatheter closure of an intracardiac defect without a permanent implant is technically feasible. Achievement of improved primary closure rates through technique and device modifications will warrant randomized clinical comparison to permanently implanted devices.


Journal of Interventional Cardiology | 2005

Atrial and ventricular septal defects can safely be closed by percutaneous intervention.

Ralph Hein; Franziska Büscheck; Evelyn Fischer; Michaela Leetz; Margareth Taaffe Yves Bayard; Stefan Ostermayer; Madlen Reschke; Klaus Lang; Albrecht Römer; Neil Wilson; Horst Sievert


Archive | 2011

Cardiovascular Forward Programming of ES cells

Evelyn Fischer; Robert David; Wolfgang-Michael Franz


Circulation | 2009

Abstract 5440: Forward Programming of Pluripotent Stem Cells Towards Distinct Cardiovascular Cell Types

Robert David; Juliane Stieber; Evelyn Fischer; Stefan Brunner; Christoph Brenner; Susanne Pfeiler; Florian Schwarz; Wolfgang-Michael Franz


Circulation | 2006

Abstract 1935: Single Center Results of PFO Closure without an Implantable Device

Corinna Heinisch; Andreas Baranowski; Nico Majunke; Marijke Skowasch; Evelyn Fischer; Michaela Leetz; Nina Wunderlich; Horst Sievert


Circulation | 2006

Abstract 3675: Thrombus Formation on ASD and PFO Devices: Frequency and Clinical Importance

Andreas Baranowski; Marijke Skowasch; Ilona Hofmann; Nicolas Majunke; Michaela Leetz; Evelyn Fischer; Margaret Taaffe; Ralph Hein; Madlen Reschke; Corinna Heinisch; Y Bayard; Franziska Bueschek; Stefan Ostermayer; Kai Billinger; Greg Robertson; Nina Wunderlich; Neil Wilson; Horst Sievert


American Journal of Cardiology | 2006

Percutaneous left atrial appendage occlusion (PLAATO) for stroke prevention: Experience with 180 patients

Y Bayard; Heyder Omran; Petr Neuzil; Leif Thuesen; M Pichler; Edward Rowland; Angelo Ramondo; Witold Rużyłło; Werner Budts; Gilles Montalescot; Pedro Brugada; Patrick W. Serruys; Alec Vahanian; Jean-Francois Piechaud; Antonio L. Bartorelli; Jean Marco; Peter Probst; Karl-Heinz Kuck; Stefan U Ostermayer; Franziska Büschek; Michaela Leetz; Evelyn Fischer; Corinna Heinisch; Hildegard Lissmann-Jensen; Horst Sievert


Journal of the American College of Cardiology | 2005

Left atrial appendage occlusion to prevent stroke in sub-optimal warfarin candidates: Current results of the European multicenter registry trial

Evelyn Fischer; Heyder Omran; Leif Thuesen; M Pichler; Edward Rowland; Antonio L. Bartorelli; Pedro Brugada; Patrick W. Serruys; Werner Budts; Angelo Ramondo; Alec Vahanian; Peter Probst; Gilles Montalescot; Jf Piechaud; Karl-Heinz Kuck; Witold Rużyłło; Jean Marco; T Wichter; E Garcia; Eustaquio Onorato; Y Bayard; Stefan Ostermayer; Franziska Büscheck; Michaela Leetz; Horst Sievert

Collaboration


Dive into the Evelyn Fischer's collaboration.

Top Co-Authors

Avatar

Horst Sievert

MedStar Washington Hospital Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Edward Rowland

St Bartholomew's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Corinna Heinisch

MedStar Washington Hospital Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge